Abbott has secured the US Food and Drug Administration’s breakthrough designation for a wearable device that will continuously monitor users' blood glucose and ketone levels.
The announcement comes just months after the company first announced plans for its Lingo line of consumer biowearables, including ketone, lactate and alcohol monitors, at the CES 2022 convention in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?